89Zr-DFO-Atezolizumab ImmunoPET/CT in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 2, 2019

Primary Completion Date

January 15, 2026

Study Completion Date

January 15, 2027

Conditions

Renal Cell Carcinoma

Interventions

DRUG

89Zr-DFO-Atezolizumab

89Zr-DFO-Atezolizumab infusion

PROCEDURE

Positron Emission Tomography/Computed Tomography

PET/CT scan 7 days (± 1 day) after infusion of 89Zr-DFO-Atezolizumab.

Trial Locations (1)

RECRUITING

UT Southwestern Medical Center, Dallas

All Listed Sponsors

lead

James Brugarolas

OTHER